Vita Life Sciences forecasts strong half-year revenue growth
Vita Life Sciences (ASX:VLS) announced its financial guidance for the half-year ending June 30, forecasting sales to land between $46.3 million and $47.3 million, up from the $45.5 million reported in H1 2025.
Pre-tax profit is expected to remain steady or trend slightly higher at $6.8 million to $7.3 million, compared to $6.8 million in the prior corresponding period.
The company anticipates solid revenue growth across its established Australian and Malaysia/Singapore markets; however, this growth is expected to be partially offset by reduced export volumes to China, driven by a shifting regulatory environment and evolving channel dynamics.
Despite tougher macroeconomic conditions, Vita Life Sciences attributes its stable profit outlook to ongoing cost discipline and high-quality underlying earnings.
Management highlighted a strong balance sheet characterised by substantial cash reserves, zero borrowings, and steady cash generation to support its long-term strategic priorities.
